Claims for Patent: 8,163,291

Summary for Patent: 8,163,291

Title:	Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
Abstract:	The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity.
Inventor(s):	Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Woodland Park, NJ)
Assignee:	IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:	12/468,589
Patent Claims:	1. A method of delivering a diagnostic or therapeutic agent comprising: a) obtaining a homodimer, each monomer of the homodimer comprising a dimerization and docking domain (DDD) of human protein kinase A regulatory subunit wherein the DDD consists the sequence of SEQ ID NO: 1 (DDD1) or SEQ ID NO: 2 (DDD2) and, wherein the DDD peptide sequences bind together to form a homodimer and the homodimer comprises at least one diagnostic or therapeutic agent; and b) administering the homodimer to a subject. 2. The method of claim 1, wherein the two DDD peptide sequences of the homodimer are covalently attached to each other by disulfide bonds. 3. The method of claim 1, wherein each monomer further comprises an antigen-binding antibody fragment that binds to a tumor-associated antigen (TAA). 4. The method of claim 3, wherein each monomer is a fusion protein comprising said DDD peptide sequence of SEQ ID NO: 2 and an antigen-binding antibody fragment. 5. The method of claim 4, wherein the monomer further comprises a linker peptide between the antigen-binding antibody fragment and the DDD. 6. The method of claim 3, wherein the antigen-binding antibody fragment is chemically linked to the DDD peptide sequence. 7. The method of claim 3, wherein the antigen-binding antibody fragment is selected from the group consisting of a Fab fragment, a Fab' fragment, a single domain antibody (DAB) and a single chain Fv (scFv). 8. The method of claim 3, wherein the antigen-binding antibody fragment binds to a tumor-associated antigen (TAA) and the therapeutic agent is an anti-cancer therapeutic agent. 9. The method of claim 8, wherein the tumor-associated antigen is selected from the group consisting of carbonic anhydrase IX, alpha-fetoprotein, antigen specific for A33 antibody, BrE3-antigen, CA125, CD1, CD1a, CD3, CD5, CD15, CD16, CD19, CD20, CD21, CD22, CD23, CD25, CD30, CD33, CD38, CD45, CD74, CD79a, CD80, CD138, colon-specific antigen-p (CSAp), CEA (CEACAM5), CEACAM6, EGFR, EGP-1, EGP-2, Ep-CAM, Flt-1, Flt-3, folate receptor, G250 antigen, HLA-DR, human chorionic Gonadotropin (HCG) and its subunits, HER2/neu, hypoxia inducible factor (HIF-1), Ia, IL-2, IL-6, IL-8, insulin growth factor-1 (IGF-1), KC4-antigen, KS-1-antigen, KS1-4, Le-Y, macrophage migration inhibitory factor (MIF), MAGE, MUC1, MUC2, MUC3, MUC4, NCA66, NCA95, NCA90, antigen specific for PAM-4 antibody, placental growth factor, p53, prostatic acid phosphatase, PSA, PSMA, RS5, S100, TAC, TAG-72, tenascin, TRAIL receptors, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis antigens, VEGF, ED-B fibronectin, and 17-1A-antigen. 10. The method of claim 8, wherein the antigen-binding antibody fragment is a fragment of an antibody selected from the group consisting of anti-CEA (hMN-14), anti-CD20 (hA20), anti-CD22 (hLL2), anti-CD74 (hLL1), anti-MUC-1 (hPAM4), anti-CD14, anti-CD111, omalizumab, muromonab, abciximab, infliximab and palivizumab. 11. The method of claim 3, wherein the antigen-binding antibody fragment comprises an immunoglobulin light chain (VL-CL) or an immunoglobulin Fc domain (CH2-CH3). 12. The method of claim 11, wherein the cysteine at the carboxyl-terminus of the CL that connects the CL to CH1 is deleted or mutated to a non-cysteine. 13. The method of claim 3, wherein the antigen-binding antibody fragment is a fragment of a human, humanized or chimeric antibody. 14. The method of claim 1, wherein the therapeutic agent is selected from the goup consisting of a chemotherapeutic agent, a cytokine, a chemokine, an anti-angiogenic agent, an apoptotic agent, a drug, a prodrug, a toxin, an enzyme, a radioisotope, an immunomodulator, an antibiotic and a hormone. 15. The method of claim 14, wherein the drug is selected from the group consisting of abrin, amantadine, amoxicillin, amphotericin B, ampicillin, aplidin, azaribine, anastrozole, azacytidine, aztreonam, azithromycin, bacitracin, trimethoprim/sulfamethoxazole, Batrafen, bifonazole, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, 10-hydroxycamptothecin, carbenicillin, caspofungin, carmustine, cefaclor, cefazolin, cephalosporins, cefepime, ceftriaxone, cefotaxime, celecoxib, chlorambucil, chloramphenicol, ciprofloxacin, cisplatin, irinotecan (CPT-11), SN-38, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, diphtheria toxin, DNase I, doxorubicin, 2-pyrrolinodoxorubicine (2P-DOX), doxycycline, cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, ethinyl estradiol, estramustine, estrogen receptor binding agents, etoposide, etoposide glucuronide, etoposide phosphate, erythrocycline, erythromycin, flagyl, farnesyl-protein transferase inhibitors, floxuridine (FUdR), 3',5'--O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, fluorouracil, fluoxymesterone, ganciclovir, gentamycin, gelonin, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosfamide, isoniazid, itraconazole, kanamycin, ketoconazole, L-asparaginase, leucovorin, lomustine, mechlorethamine, medroprogesterone acetate, megestrol acetate, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, minocycline, naftifine, nalidixic acid, neomycin, navelbine, nitrosurea, nystatin, ranpirnase, oxacillin, paromomycin, penicillin, pentamidine, piperacillin-tazobactam, phenyl butyrate, prednisone, procarbazine, paclitaxel, pentostatin, pokeweed antiviral protein, PSI-341, semustine, rifabutin, rifampin, rimantadine, streptomycin, sulfamethoxazole, sulfasalazine, streptozocin, tamoxifen, taxanes, taxol, testosterone propionate, tetracycline, thalidomide, thioguanine, thiotepa, teniposide, topotecan, transplatinum, trimethoprim sulfamethoxazole, uracil mustard, valacyclovir, vancomycin, vinblastine, vinorelbine, vincristine, zanamir and zithromycin. 16. The method of claim 15, wherein the toxin is selected from the group consisting of a bacterial toxin, a plant toxin, ricin, abrin, a ribonuclease (RNase), DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtherin toxin, Pseudomonas exotoxin, Pseudomonas endotoxin, Ranpirnase (Rap) and Rap (N69Q). 17. The method of claim 14, wherein the immunomodulator is selected from the group consisting of a cytokine, a stem cell growth factor, a lymphotoxin an interleukin, a colony-stimulating factor, interferon-.alpha., interferon-.beta., interferon-.gamma., and the stem cell growth factor designated "S1 factor." 18. The method of claim 14, wherein the cytokine is selected from the group consisting of human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor, prostaglandin, fibroblast growth factor, prolactin, placental lactogen, OB protein, tumor necrosis factor-.alpha., tumor necrosis factor-.beta., mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, integrin, thrombopoietin (TPO), NGF-.beta., platelet-growth factor, TGF-.alpha., TGF-.beta., insulin-like growth factor-I, insulin-like growth factor-II, erythropoietin (EPO), osteoinductive factor, interferon-.alpha., interferon-.beta., interferon-.gamma., macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (G-CSF), IL-1, IL-1.alpha., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, LIF, kit-ligand, FLT-3, angiostatin, thrombospondin, endostatin and LT. 19. The method of claim 1, wherein the diagnostic or therapeutic agent is selected from the group consisting of .sup.225Ac, .sup.211At, .sup.212Bi, .sup.213Bi, .sup.14C, .sup.51Cr, .sup.36Cl, .sup.45Ti, .sup.57Co, .sup.58Co, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.166Dy, .sup.152Eu, .sup.18F, .sup.67Ga, .sup.68Ga, .sup.195mHg, .sup.166Ho, .sup.3H, .sup.111In, .sup.123I, .sup.124I, .sup.125I, .sup.131I, .sup.52Fe, .sup.59Fe, .sup.177Lu, .sup.191Os, .sup.212Pb, .sup.32P, .sup.33P, .sup.142Pr, .sup.195mPt, .sup.223Ra, .sup.186Re, .sup.188Re, .sup.189Re, .sup.47Sc, .sup.75Se, .sup.111Ag, .sup.153Sm, .sup.89Sr, .sup.35S, .sup.161Tb, .sup.94mTc, .sup.99mTc, .sup.86Y, .sup.90Y, and .sup.89Zr. 20. The method of claim 1, wherein the diagnostic agent is selected from the group consisting of a radioisotope, an imaging agent, a dye, an enzyme, a fluorescent agent, a chemiluminescent agent, a bioluminescent agent, a paramagnetic ion and an ultrasound label. 21. The method of claim 20, wherein the imaging agent is selected from the group consisting of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) erbium (III), lanthanum (III), gold (III), lead (II) and bismuth (III). 22. The method of claim 20, wherein the fluorescent agent is selected from the group consisting of Alexa 350, Alexa 430, AMCA, aminoacridine, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, 5-carboxy-4',5'-dichloro-2',7'-dimethoxy fluorescein, 5-carboxy-2',4',5',7'-tetrachlorofluorescein, 5-carboxyfluorescein, 5-carboxyrhodamine, 6-carboxyrhodamine, 6- carboxytetramethyl amino, Cascade Blue, Cy2, Cy3, Cy5,6-FAM, dansyl chloride, Fluorescein, HEX, 6-JOE, NBD (7-nitrobenz-2-oxa-1,3-diazole), Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, phthalic acid, terephthalic acid, isophthalic acid, cresyl fast violet, cresyl blue violet, brilliant cresyl blue, para-aminobenzoic acid, erythrosine, phthalocyanines, azomethines, cyanines, xanthines, succinylfluoresceins, rare earth metal cryptates, europium trisbipyridine diamine, a europium cryptate or chelate, diamine, dicyanins, La Jolla blue dye, allopycocyanin, allococyanin B, phycocyanin C, phycocyanin R, thiamine, phycoerythrocyanin, phycoerythrin R, REG, Rhodamine Green, rhodamine isothiocyanate, Rhodamine Red, ROX, TAMRA, TET, TRIT (tetramethyl rhodamine isothiol), Tetramethylrhodamine, and Texas Red. 23. The method of claim 1, wherein the homodimer further comprises one or more effectors or carriers conjugated to the homodimer by either covalent or non-covalent linkage. 24. The method of claim 23, wherein the effector is selected from the group consisting of a diagnostic agent, a therapeutic agent, a chemotherapeutic agent, a radioisotope, an imaging agent, an anti-angiogenic agent, a cytokine, a chemokine, a growth factor, a drug, a prodrug, an enzyme, a ligand for a cell surface receptor, a chelator, an immunomodulator, a hormone, a photodetectable label, a dye, a toxin, a contrast agent, a paramagnetic label, an ultrasound label, a pro-apoptotic agent, a liposome and a nanoparticle. 25. The method of claim 23, wherein the effectors or carriers are chemically cross-linked to the homodimer. 26. The method of claim 23, wherein the homodimer is attached to two or more effectors or two or more carriers. 27. The method of claim 26, wherein the two or more carriers or two or more effectors are either identical or different. 28. The method of claim 23, wherein the one or more carriers comprise at least one diagnostic or therapeutic agent.

Details for Patent 8,163,291

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2025-04-06
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2025-04-06
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2025-04-06
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2025-04-06
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2025-04-06
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		2025-04-06
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-04-06